Cancer Prevention and Control Research Program

项目总结/摘要 癌症预防和控制 埃默里大学温希普癌症研究所癌症预防和控制（CPC）项目（Winship） 协调和促进中心内所有与癌症预防和控制有关的研究活动。的 CPC计划的目标是通过创新研究和社区学习来产生知识， 这将改变癌症的预防和护理，并减少癌症负担在温希普的集水区， 格鲁吉亚州及其他地区。CPC有四个科学主题：（1）癌症流行病学-实现高质量 监测癌症负担并确定风险因素，如生物、行为、社会和政策因素， 和环境暴露，为有针对性的干预措施和战略提供信息，以减少格鲁吉亚的癌症风险; (2)干预措施-重点关注HPV疫苗接种率、减少烟草使用的个人行为干预措施 并防止体重增加，政策和制度层面的变化与广泛的最终目标 实施有效的策略;（3）癌症生存和症状管理-以治疗为重点- 相关的早期影响，包括患者报告的结果，大脑中的生物行为变化，儿童和 青少年癌症幸存者过渡到初级保健，以及心血管疾病等晚期影响， 实质上影响癌症患者和幸存者的生活质量;以及（4）癌症护理质量-进行 以人口为基础的研究，描述，解释和预测卫生保健干预措施的影响， 其他因素对坚持护理，癌症护理的质量，护理的不公平性和结果。领导下 关于Timothy L. Lash，DSc，MPH（领导者）和Mylin托雷斯，MD（共同领导者），CPC包括53名核心成员 代表16个不同的部门在医学院，护士内尔霍奇森伍德拉夫学校， 和埃默里大学罗林斯公共卫生学院。这种多样化的成员构成了丰富的研究 为下一代癌症研究人员提供培训环境。方案协调会不断与 社区外展和参与（COE），为集水区优先事项的研究提供信息，并积极 致力于为代表性不足的群体促进生物医学科学事业。这个高度合作的团体 的研究人员在当前资助期间发表了1，074篇与癌症相关的科学文章。其中，275 (26 290项（27%）为方案内合作，779项（73%）为方案间合作， 与外部学术组织合作。144篇（13%）发表在具有影响力的期刊上 因子≥ 10。截至2021年底，CPC成员每年在癌症相关研究中拥有1450万美元 资金，其中1130万美元是同行评审的（78%），860万美元（59%）是直接从NCI获得的。 来自NCI的资金从2016年的440万美元增加到2021年的860万美元。值得注意的新资金包括 一项R 01，用于支持在格鲁吉亚癌症登记处增加复发监测（总额370万美元， R 01 CA 234538，Ward/Lash），并更新了疾病控制和预防中心（CDC）的资金， 埃默里预防研究中心（U48 DP 006377，Kegler），专注于格鲁吉亚农村的癌症预防。

PROJECT SUMMARY/ABSTRACT CANCER PREVENTION AND CONTROL PROGRAM The Cancer Prevention and Control (CPC) Program of Winship Cancer Institute of Emory University (Winship) coordinates and promotes all cancer prevention and control-related research activities within the center. The goal of CPC Program is to generate knowledge through innovative research and learning from the community, that will transform cancer prevention and care and reduce the cancer burden in Winship’s catchment area, the state of Georgia, and beyond. CPC has four scientific themes: (1) Cancer Epidemiology - to achieve high quality surveillance of the cancer burden and identify risk factors such as biological, behavioral, social and policy factors, and environmental exposures, to inform targeted interventions and strategies to reduce cancer risk in Georgia; (2) Interventions - focus on HPV vaccination uptake, individual behavioral interventions to reduce tobacco use and to prevent weight gain, and policy and systems-level changes with the ultimate goal of broad-scale implementation of effective strategies; (3) Cancer Survivorship and Symptom Management - focus on treatment- related early effects, including patient-reported outcomes, biobehavioral changes in the brain, childhood and adolescent cancer survivors transition to primary care, and late effects such as cardiovascular disease, which substantially affect the quality-of-life of cancer patients and survivors; and (4) Quality of Cancer Care - to conduct population-based research that describes, interprets, and predicts the impact of health care interventions and other factors on adherence to care, quality of cancer care, inequities in care, and outcomes. Under the leadership of Timothy L. Lash, DSc, MPH (leader) and Mylin Torres, MD (co-leader), CPC includes 53 core members representing 16 different departments within the School of Medicine, Nell Hodgson Woodruff School of Nursing, and Rollins School of Public Health at Emory University. This diverse membership furnishes a rich research training environment for the next generation of cancer researchers. CPC engages in ongoing interactions with Community Outreach and Engagement (COE) to inform research on catchment area priorities and actively engages in promoting biomedical scientific careers for under-represented groups. This highly collaborative group of researchers published 1,074 cancer-relevant scientific articles during the current funding period. Of these, 275 (26%) were intra- and 290 (27%) were inter-programmatic collaborations and 779 (73%) represented a collaboration with an external academic organization. 144 (13%) were published in journals with an impact factor of ≥ 10. As of end of 2021, CPC members held $14.5 million in annual total cancer-relevant research funding, of which $11.3 million is peer-reviewed (78%) and $8.6 million (59%) was awarded directly from NCI. Funding from NCI increased from $4.4 million in 2016 to $8.6 million in 2021. Notable new funding includes an R01 to support the addition of recurrence surveillance to the Georgia Cancer Registry ($3.7M total, R01CA234538, Ward/Lash), and renewed Centers for Disease Control and Prevention (CDC) funding of the Emory Prevention Research Center (U48DP006377, Kegler), focused on cancer prevention in rural Georgia.